Ikena Oncology Stock Current Liabilities
| IKNA Stock | USD 1.37 0.06 4.58% |
Ikena Oncology fundamentals help investors to digest information that contributes to Ikena Oncology's financial success or failures. It also enables traders to predict the movement of Ikena Stock. The fundamental analysis module provides a way to measure Ikena Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ikena Oncology stock.
The current year's Total Current Liabilities is expected to grow to about 14.9 M, whereas Non Current Liabilities Total is forecasted to decline to about 4.6 M.
Ikena | Current Liabilities |
Ikena Oncology Company Current Liabilities Analysis
Ikena Oncology's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Ikena Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Ikena Oncology is extremely important. It helps to project a fair market value of Ikena Stock properly, considering its historical fundamentals such as Current Liabilities. Since Ikena Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ikena Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ikena Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
Ikena Current Liabilities Historical Pattern
Today, most investors in Ikena Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Ikena Oncology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Ikena Oncology current liabilities as a starting point in their analysis.
Ikena Oncology Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Ikena Total Current Liabilities
Total Current Liabilities |
|
At present, Ikena Oncology's Total Current Liabilities is projected to increase significantly based on the last few years of reporting.
In accordance with the recently published financial statements, Ikena Oncology has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Ikena Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ikena Oncology's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ikena Oncology could also be used in its relative valuation, which is a method of valuing Ikena Oncology by comparing valuation metrics of similar companies.Ikena Oncology is currently under evaluation in current liabilities category among its peers.
Ikena Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | (51.23 M) | ||||
| Shares Outstanding | 48.26 M | ||||
| Shares Owned By Insiders | 4.54 % | ||||
| Shares Owned By Institutions | 87.75 % | ||||
| Number Of Shares Shorted | 154.14 K | ||||
| Price To Earning | 3.89 X | ||||
| Price To Book | 0.52 X | ||||
| Price To Sales | 43.56 X | ||||
| Gross Profit | (30.88 M) | ||||
| EBITDA | (58.97 M) | ||||
| Net Income | (49.23 M) | ||||
| Cash And Equivalents | 192.81 M | ||||
| Cash Per Share | 5.32 X | ||||
| Total Debt | 7.52 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 6.98 X | ||||
| Book Value Per Share | 2.61 X | ||||
| Cash Flow From Operations | (46 M) | ||||
| Short Ratio | 0.91 X | ||||
| Earnings Per Share | (1.02) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 10 | ||||
| Beta | 0.5 | ||||
| Market Capitalization | 66.11 M | ||||
| Total Asset | 141.51 M | ||||
| Retained Earnings | (331.62 M) | ||||
| Working Capital | 116.39 M | ||||
| Net Asset | 141.51 M |
About Ikena Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ikena Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ikena Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ikena Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Ikena Oncology Piotroski F Score and Ikena Oncology Altman Z Score analysis. For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.02) | Revenue Per Share | Quarterly Revenue Growth (0.88) | Return On Assets | Return On Equity |
The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.